Lung cancer kills more people than any other kind of cancer, even though 10-year survival rates approach 90 percent when detected in the earliest stages.
On Wednesday, Medtronic, which operates in Minnesota, touted new study data for its SuperDimension bronchoscope navigation system. It shows the system successfully detected early signs of lung cancer in a good proportion of patients in an all-comers population that included community hospitals and academic medical centers.
Data from the NAVIGATE study, published in the Journal of Thoracic Oncology, showed that in U.S. patients who got SuperDimension imaging and biopsies and were diagnosed with cancer, 65 percent of those diagnoses were for Stage I or Stage II cancers.
"The ability to diagnose early and stage in a single procedure may improve survival and reduce treatment costs," study authors wrote.
Staging in a single procedure means that a patient can be imaged, biopsied and diagnosed to a specific "stage" of lung cancer with one procedure instead of multiple procedures.
Lung cancer can be diagnosed from Stage 0 to Stage IV.
SuperDimension was a Minnesota-based company before it was acquired by Covidien, and later acquired by Medtronic. The SuperDimension system consists of several components that together give doctors a way to directly look at and then take samples of nodules deep in the lungs that are hard to access any other way.
The system includes in-room navigation that works like a local GPS system, and a hand-held tool used by the physician that reaches deep into the lungs.